Aim:

To determine the effect of sildenafil citrate on the nocturnal penile erections (i.e. time to onset, the duration of erection, and the interval between first and second erections) of healthy young men.

Methods:

Twenty-two potent men, 23–29 years old, were recruited for the study. All subjects completed three sessions over consecutive nights using the RigiScan monitoring device (Dacomed, Minneapolis, USA). After a first night of adaptation, night 2 records were their baseline values, and on night 3 they received 100 mg of sildenafil citrate. Statistical comparisons were done between the second and third night data.

Results:

The mean time to onset of the first erection with sildenafil citrate was (34 18) min, whereas it was (74 24) min (P < 0.001) without sildenafil citrate. The number of erections observed during the first 5 h after sildenafil citrate medication was 3.6 0.5 in contrast to 2.4 0.5 with no medication (P = 0.001). The interval between first and second erections was shorter with sildenafil citrate: (52 26) min vs. (85 34) min (P = 0.01). The duration of the last erection was statistically significantly longer with the sildenafil citrate: (64 33) min vs. (42 28) min (P < 0.01).

Conclusion:

Healthy young men achieved erection within 34 min after sildenafil citrate administration, which is shorter than the 1 h interval proposed by the manufacturer. The interval between the first and second erections was shorter and the duration of the last nocturnal erection was longer.

References

1. Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update of sildenafil citrate efficacy and safety. Int J Clin Pract 2001; 55: 115–28. | PubMed | ChemPort |
2. McCullough AR. Four-year review of sildenafil citrate. Rev Urol 2002 Suppl; 4: S26. | PubMed |
3. Rosenstock HA, Axelrad SD. Erectile dysfunction: on the efficacy of a phosphodiesterase inhibitor in patients with multiple risk factors. Asian J Androl 1999; 1: 211–4. | PubMed | ChemPort |
4. Rosenstock HA, Axelrad SD. Erectile dysfunction: on the efficacy of a phosphodiesterase inhibitor in patients with concurrent sex therapy. Asian J Androl 1999; 1: 207–10. | PubMed | ChemPort |
5. Padma-nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4–year update on the safety of sildenafil citrate (Viagra). Urology 2002; 60: 67–90. | Article | PubMed | ISI |
6. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile dysfunction. Asian J Androl 2004; 6: 117–20. | PubMed | ISI | ChemPort |
7. Huang XB, Xiong CL, Yu CG, Zhou JL, Shen JY. Effect of sildenafil citrate on penile erection of rhesus macaques. Asian J Androl 2004; 6: 233–5. | PubMed | ChemPort |
8. Low WY, Ng CJ, Tan NC, Choo WY, Tan HM. Management of erectile dysfunction: barriers faced by general practitioners. Asian J Androl 2004; 6: 99–104. | PubMed | ISI |
9. Kilinc K, Gunduz MI, Gumus BH, Vatansever S, Kaymaz F. Ultrastructural effect of sildenafil citrate on corpus cavernosum and other genital organs in female rats. Asian J Androl 2003; 5: 37–41. | PubMed | ChemPort |
10. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53: 5S–12S. | Article | PubMed | ChemPort |
11. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002; 53: 61S–65S. | Article | PubMed | ISI | ChemPort |
12. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52. | PubMed | ChemPort |
13. Sjöqvist F, Borga D, Dahl ML, Orme ML. Fundamentals of clinical pharmacology. In: Speight TM, Holford NHG, editors. Avery's Drug Treatment, 4th ed. Auckland: Adis International; 1997. p 1–73.
14. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404. | Article | PubMed | ISI | ChemPort |
15. Padma-Nathan H, Stecher VC, Sweeney M, Orazem J, Tseng LJ, Deriesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3. | Article | PubMed | ISI | ChemPort |
16. Montorsi F, Maga T, Strambi LF, Salonia A, Barbieri L, Scattoni V, et al. Sildenafil taken at bedtime significantly increases nocturnal erection: results of a placebo-controlled study. Urology 2000; 56: 906–11. | Article | PubMed | ChemPort |
17. Yaman O, Tokatli Z, Inal T, Anafarta K. Effect of sildenafil on nocturnal erections of potent men. Int J Impot Res 2003; 15: 117–21. | Article | PubMed | ChemPort |
18. Mondaini N, Ponchietti R, Muir GH, Montorsi F, Di Loro F, Lombardi G, et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res 2003; 15: 225–8. | Article | PubMed | ChemPort |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.